著者

Matsushita Takashi Fujimoto Manabu Hasegawa Minoru Komura Kazuhiro Takehara Kazuhiko Tedder Thomas F. Sato Shinichi

出版者

Elsevier

雑誌

American Journal of Pathology (ISSN:00029440)

巻号頁・発行日

vol.168, no.3, pp.812-821, 2006-03-01

被引用文献数

90

---

Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease of the central nerve system that is considered a T helper type 1 (Th1)-mediated autoimmune disease. EAE currently serves as an experimental animal model for multiple sclerosis in human. Cytokines, such as interferon-γ and interleukin-10, play a key role in the development and remission of EAE. Recent studies have also shown a role for B cells in the pathogenesis of EAE. Therefore, we examined the role of CD19, a B cell-specific surface molecule that defines signaling thresholds critical for B-cell responses and autoimmunity, on the development of EAE. Following immunization with myeiin oligodendrocyte glycoprotein (MOG) peptide, CD19-deficient (CD19-/-) mice exhibited higher clinical and pathological severity scores of EAE than wild-type mice. The increased severity of EAE in CD19-/- mice was associated with polarized Th1 cytokines in the inflamed central nerve system but not with anti-MOG antibodies in the serum. MOG-primed CD19-/- B cells produced high levels of interferon-γ, and transfer of MOG-primed CD19-/- B cells to wild-type mice worsened the disease. Thus, CD19 modulates the Th1/Th2 cytokine balance in B cells and plays a critical role as a suppressive molecule in the development of EAE. Copyright © American Society for Investigative Pathology.